Recording Date: March 7, 2019
Presenter: Josiah Allen
Pharmacogenomic (PGx) testing is a relatively recent innovation in care and has brought with it the hope of utilizing genetic information to better tailor medical interventions. While the widespread use of PGx testing poses a significant potential benefit to the health system, our understanding of the cost-effectiveness of PGx testing is still maturing. Josiah's webinar and whitepaper, An Economic Evaluation of Pharmacogenomic Testing, covers current knowledge surrounding PGx testing with regard to cost-effectiveness and highlights where evidence clearly supports its use.
- Analysis of six patient-focused studies
- Relevance of PGx to significant patient populations
- Cost-effectiveness and cost savings of genetically-guided strategies
- Pharmacogenomics as a new standard of care for prescribers